Abstract We report a new case of hepatitis C-associated osteosclerosis (HCAO). The clinical presentation of the patient was an acquired deep severe bone pain with increased serum bone alkaline phosphatase activity (up to 12 times the upper limit of normal), and generalized bone sclerosis, temporally related to the hepatitis Cvirus (HCV) infection. We documented in this patient an increase of circulating osteoprotegerin (OPG), and a concentration of circulating receptor activator for nuclear factor-kB ligand (RANKL) below the lower limit of the reference range. The observed abnormalities of the OPG/RANKL system may contribute to the maintenance of the positive balance of bone remodeling that characterizes patients with HCAO.
Introduction
Hepatitis C virus (HCV) is a predominantly hepatotropic virus [1] . The morbidity and mortality associated with HCV infection, however, are not only dependent on the consequences of liver disease, but also on extrahepatic manifestations. At least two of these complications (mixed cryoglobulinemia and non-Hodgkin lymphoma) are generally recognized as severe, because of their progressive course and potentially fatal outcome.
In 1992 Villareal et al. characterized a syndrome in patients infected with hepatitis C virus that featured acquired, severe, generalized osteosclerosis and hyperostosis [2] . To date, no more than 11 cases have been reported [2] [3] [4] [5] [6] [7] [8] [9] [10] . Nine patients were from the United States, one from Australia, and one from Japan. Six of these individuals had a history of i.v. drug abuse; two appear to have acquired HCV infection from blood transfusion; in one patient acupuncture is reported as a possible cause of HCV infection; in one patient the mode of transmission was not reported.
The clinical presentation of the disease is an acquired deep, mild or severe pain and tenderness of the limbs, with no record of previous fractures. Radiographs show diffuse bone sclerosis with marked cortical thickening. Calvaria and facial bones may be spared. Bone scintigraphy shows a diffuse increased uptake of radionuclide; however, bone biopsy shows normal lamellar bone with accelerated rates of skeletal formation [8] . The serum alkaline phosphatase (ALP) activity is invariably high, whereas, markers of bone resorption may be either increased [8, 9] or normal [4] . Areal bone mineral density is abnormally high. The disorder is almost certainly related to HCV; however, the pathogenesis remains incompletely understood. Khosla et al. [10, 11] demonstrated, in seven of previously reported cases of HCAO, abnormalities in the insulinlike growth factor (IGF) system featuring increased circulating levels of IGF-binding protein (IG-FBP) 2 and ''big'' IGF II, which suggest that hepatic production of growth factors that stimulate osteoblast function can be increased by HCV or, as a remote possibility, by a different parenterally transmitted agent.
Since the cloning of osteoprotegerin (OPG), which is an inhibitor of osteoclast differentiation, and of osteoprotegerin ligand (RANKL, for receptor activator of NF-kappa-B ligand), an osteoclast differentiation factor, our knowledge on the cellular and molecular basis of metabolic bone diseases has advanced considerably [12] . The OPG/RANK ligand system (with appropriate assay) was discovered subsequent to previous reported cases of HCAO, and therefore no information on the possible contribution of this pathway to the pathogenesis of osteosclerosis developing in some HCV positive patients is present in the medical literature.
Here, we describe a new subject with hepatitis Cassociated osteosclerosis (HCAO), whose viral infection was not acquired from blood transfusion or i.v. drug abuse. In this new patient we also measured serum concentrations of OPG and RANKL, and calculated the OPG/RANKL ratio.
Case report
In June 2004, a 65-year-old woman was referred to our outpatient clinic for severe pain and tenderness in both legs. Medical history revealed a diagnosis of HCV infection in March 1996. At that date, abnormal serum transaminase levels were present. Serum levels of ALP were normal. The transaminase serum levels, regularly checked from 1996, remained slightly elevated, but essentially stable. ALP activity was not checked thereafter. There was no history of blood transfusion or i.v. drug abuse, and, therefore, we have no proof of the actual route of infection in this patient. The patient's family members had no history of hepatitis. She felt generally well until the winter of 1997, when she developed aching in both limbs. Biochemical studies revealed increased serum ALP activity (about four times the upper limit of normal). Serum calcium, phosphorus, 25-Hydroxy-Vitamin D (25OHD), parathyroid hormone (PTH) and creatinine were normal. Bone biopsy of an iliac crest showed dense cortical bone with no defective bone remodeling. Tetracycline labeling was not performed. A radiograph of the pelvis and hips obtained on that occasion showed marked generalized bone sclerosis of the ilium, ischium, pubis, and femurs (Fig. 1A) . A diagnosis of Paget's bone disease was suggested by a physician, and concluded by a radiologist, who considered the bone pattern consistent with such diagnosis. No Bone sclerosis is due to both periosteal and endosteal hyperostosis, with no signs of irregular bone formation diabetes, hypertension, neuropathy or fractures were present in the past medical history. No other causes of dense bone were uncovered by medical history.
On physical examination, she appeared well-developed, with no signs of mental retardation or facial deformities. Palpation of long bones evoked an increase of pain and tenderness. A radiologic study performed in 1989 shows normally dense bones, which allows stating that the osteosclerosis was acquired.
Hepatitis C antibody (anti-HCV) and quantitative PCR for viral RNA (AmpliScreen Roche) were positive. The HCV RNA core genotype was 1B. Serological studies were negative for Hb s Ag, Hb c Ag, and EpsteinBarr virus. The patient has never received treatment with any type of interferon. Laboratory data on presentation are summarized in Table 1 . They revealed an increased ALP activity (six times the upper limit of normal). ALP isoenzyme fractionation showed that ALP was 92% bone isoform and 8% liver isoform. Osteocalcin serum level was slightly increased. Serum PTH was elevated, perhaps secondary to avid net bone formation [7] , or, in some cases, to mild primary hyperparathyroidism [13] . Serum 250HD concentration was within the normal range. Serum acid phosphatase activity was normal (<6 U/l), and the brain isoenzyme of creatine kinase (BB-CK) also expressed in osteoclasts, was undetectable [14] .
Urine deoxypyridinoline/creatinine ratio (which reflects bone resorption) was also normal. Erythrocyte sedimentation rate and complete blood count were normal.
OPG and RANKL were measured in a fasting blood sample by ELISA in a routinely performed assay using reagents supplied by Biomedica Medizinprodukte (Wien, Austria). In our hands, the method has a detection limit of 0.14 pmol/l for OPG, and of 0.08 pmol/l for RANKL. The intra-assay precision of the method was 10% for low values and 4% for high values for OPG, and 5% and 3% for low and high values, respectively, for RANKL. The mean reference values in healthy adults in our laboratory is 3.4±1.05 pmol/l for OPG, and 0.36±0.06 pmol/l for RANKL [15] . Two different samples from two healthy women (A and B) with a known concentration of OPG and RANKL were also measured in the same session, to serve as controls. OPG serum levels in our patient were 7.6 pmol/l. RANKL serum levels were 0.14 pmol/l, with an OPG/RANKL ratio of 54.2. The concentration of OPG and RANKL in the healthy subjects A and B were 3.2 pmol/l and 0.38 pmol/l, and 4.3 pmol/l and 0.44 pmol/l, respectively, consistent with the known values.
Determination of bone mineral density (BMD) was made by DXA (Norland XR36) ( Table 2) . Lumbar spine BMD (L2-L4) was 1.592 g/cm 2 (T -score = +5.46); femoral neck BMD was 1.658 g/cm 2 (T -score = +7.63).
Radiographic examination revealed bone sclerosis of the bilateral clavicle, humerus, pelvis, femurs, tibia and vertebrae (Fig. 1B) . The appearance of the skeleton was consistent, with thickened cortical bone on both periosteal and endosteal surfaces. There was no evidence of focal sclerosis or periosteal bone apposition.
A review of available skeletal radiographs taken in April 1997 and in June 2004 allowed us to observe changes in the thickness of the cortex of the hips: the thickest portion of the cortex of the lateral femoral midshaft had increased from a maximum of approximately 12 mm to a maximum of approximately 14 mm. A 99m Tc-methylene diphosphonate bone scan showed diffuse increased uptake of all major bones (Fig. 2) .
Discussion
This patient has the clinical hallmarks of hepatitis-Cassociated osteosclerosis (HCAO), a rare but wellcharacterized syndrome that apparently affects only a very small percentage of all patients infected with hepatitis C. The onset of metabolic bone abnormalities and skeletal pain temporally followed HCV infection, but as it is unclear when HCV was acquired by the patient, we cannot provide any hypothesis about the temporal relationship between exposure and the onset of HCAO. Reported cases of HCAO suggest that skeletal symptoms may occur many years after acquiring HCV infection [7] . In our patient, 1 year elapsed between the first measurement of ALP serum values (which showed normal values) and the onset of bone pain characterized by elevation in serum ALP. Despite the latency period, this pattern is consistent with the observation that the skeletal symptoms of HCAO can be the result of rapid bone accretion over a short period of time, rather than the result of a slow, excessive bone formation during many years [7] .
The pathogenesis of HCAO is still not entirely known. Khosla et al. [10] documented no common genotype or novel strain of hepatitis C in four HCAO patients. The same author demonstrated that HCAO is associated with elevated serum levels of IGF-IIE and IGFBP-2, with little or no alteration in IGF-I and IGF-II levels [11] . The combination of increased IGF-IIE and IGFBP-2 seems necessary for excess stimulation of osteoblast function and bone formation observed in HCAO patients, as patients with hepatitis C but without osteosclerosis have high IGF-IIE, but normal IGFBP-2 serum levels [10] . The mechanism(s) by which hepatitis C virus induces the reported specific abnormalities in the IGF/IGFBP system, apparently responsible for the increase in bone mass in HCAO patients, is not yet known.
We found in our patient a concentration of OPG higher than in control subjects, and a concentration of RANKL below the lower limit of the reference range. It should be stressed that the reference range for RANKL in adult healthy subjects is between 0 (undetectable) and 4.6 pmol/l, so that any detectable value below 4.6 pmol/l could be considered normal in a single patient. Conclusive data on RANKL in HCV patients are not available in the literature. However, it should be mentioned that in the study by Szalay et al. [16] , RANKL levels measured in 16 women with chronic HCV infection were elevated if compared with the control group, but they were undetectable in the four HCV patients with the highest ALP activity. Information on bone status in these four patients was not given. Szalay et al. suggest that cholestasis might affect RANKL values, but this does not apply to our patient, whose ALP was almost entirely bone isoform. The RANKL level was clearly not increased in our patient. This may reflect the lack of a compensatory response to enhanced osteoblast activity and positive balance of bone remodeling in the HCAO. The osteoclast activity is, in fact, not increased in our patient. Instead, the ''normal'' urinary excretion of deoxypyridinoline may actually reflect some suppression of resorption.
OPG is produced mostly by osteoblasts, and if there is an increased osteoblast function in HCAO, one would expect higher OPG levels in HCAO than in healthy individuals. OPG acts as a decoy receptor for RANKL and prevents its interaction with RANK, a cell surface receptor on pre-osteoclasts and osteoclasts [17, 18] . OPG/RANKL ratio as high as 54.2 observed in our HCAO patient may reflect an enhanced osteoblast activity, which may favor bone apposition and contribute to maintaining a positive bone remodeling balance. Hepatitis C virus induces overexpression of the protoocogene c-fos and of other oncogenes [19] . Since c-fos and other members of the activating protein 1 (AP-1) transcription factor complex, like DFosB and fos-related antigen 1 (fra -1), are involved in increased bone formation, osteosclerosis and osteopetrosis [20, 22] , it would be interesting to evaluate whether the osteosclerosis observed in HCV-infected patients is dependent on up-regulation of these factors.
It is possible that HCAO is more than just a rare although fascinating disorder, and that its actual prevalence among HCV patients may be underestimated. We propose that physicians caring for patients with hepatitis C should encourage regular serum ALP testing, in order to identify patients with increased bone formation.
